2026 UK comparison: GP smoking‑cessation referrals vs community ‘vape clinics’ — Ealing case study, quit rates and cost‑per‑quitter

Introduction

England’s approach to smoking cessation is changing fast. Between 2024 and 2026, major policy shifts — most notably the Swap to Stop programme — have pushed vaping into the mainstream of quit attempts. But what works best at a local level: traditional GP referrals into stop‑smoking services, or community‑led ‘vape clinics’ that combine starter kits with targeted behavioural support? This article compares the two, using Ealing’s 2024/25 JSNA figures as a case study, and sets out practical recommendations for commissioners, clinicians and smokers.

Head‑to‑head: key features compared

1. Reach and referral activity

GP referrals / traditional stop‑smoking services: In Ealing 2024/25 there were 769 referrals from local services. That equated to 1,155 referrals per 100,000 smokers — the second lowest in North West London (NWL). Low referral activity has been a consistent challenge in many areas, especially where primary care engagement is limited.

Community vape clinics: Typically rely on proactive outreach and walk‑in availability. The Swap to Stop policy (and associated investment) was explicitly designed to scale free vape starter kits and community support, aiming to reach many smokers who do not engage with GP referrals.

2. Quit rates and outcomes (Ealing case study)

Ealing JSNA (2024/25): of 769 referrals, 454 people set a quit date (≈59% of referrals) and 227 people were CO‑validated quitters. That means 227 validated quits out of 454 set quit dates — a 50% conversion from set date to validated quit — and a validated‑quit rate of ≈29.5% when measured against initial referrals.

Vape clinics: Evidence is still emerging at scale, but national-level analysis matters: a 2026 paper in Addiction found Swap to Stop was associated with a 1.5 percentage‑point increase in the proportion of people using vapes in past‑year quit attempts in England — a sign that vape‑focused programmes are changing behaviour. National guidance from NCSCT (March 2026) also confirms that nicotine vapes are effective cessation aids and recommends integrating them into local services, especially alongside behavioural support.

3. Cost‑per‑quitter

GP / local stop‑smoking referrals (Ealing): The JSNA reports a local cost per quitter of £2,063 — the highest in NW London. That figure covers programme costs as reported locally and reflects relatively low referral volumes combined with service running costs.

Community vape clinics: Cost‑per‑quitter economics can look very different. Central government planning documents for Swap to Stop show major new investment to scale free starter kits and support — examples include an additional £5m in the near term, followed by plans of around £15m per year and up to ~£45m over two years for national rollout in planning documents. If scaled to support close to 1 million smokers, those sums imply a relatively low programme cost per person when delivered at scale (rough arithmetic: £15m divided by 1m people ≈ £15 per person), although this excludes local staff, premises and behavioural support costs. Importantly, consumer savings from switching to vaping can be substantial: 2026 market analyses suggest heavy smokers may save up to ~£4,000–£5,000 per year — savings that change the wider economic picture of quitting.

4. Service quality and behavioural support

NCSCT emphasises that the best outcomes come from combining nicotine products with behavioural support. GP referrals often link to structured stop‑smoking programmes that include behaviour change sessions, whereas community vape clinics vary: a 2026 cross‑sectional survey of UK cessation providers found growing demand for vaping‑cessation support but patchy provision — roughly 40% of providers reported at least weekly demand for vaping support and fewer than half offered tailored services.

Pros and cons

GP referrals / traditional stop‑smoking services

• Pros: Established pathways, clinical oversight, CO‑validation and formal recording; often integrated with long‑term medical records and support for pharmacotherapy.
• Cons: In Ealing, low referral volumes and high cost‑per‑quitter (£2,063); may be less accessible to smokers who don’t routinely use primary care; slower to adopt vaping in some areas until recent NCSCT guidance.

Community vape clinics

• Pros: High accessibility, rapid adoption of vaping‑based interventions, potential for lower programme cost per person when scaled, and strong appeal to smokers motivated by cost savings. Swap to Stop evidence shows a measurable rise in vape‑use during quit attempts.
• Cons: Variation in quality and availability of behavioural support; fewer services currently offer tailored vaping‑cessation programmes despite high demand; local commissioning and staff training required to ensure CO‑validation and long‑term abstinence.

Recommendations — which is best for whom?

The right choice depends on the smoker and local commissioning priorities. Below are practical recommendations for different use cases.

1. Smokers who want medical oversight (complex comorbidity, pregnancy, heavy nicotine dependence)

GP referrals and formal stop‑smoking services remain the safest starting point because they offer clinical assessment and recorded follow‑up. These pathways can and should integrate vapes following NCSCT guidance.

2. Cost‑sensitive heavy smokers

Community vape clinics can offer quick access to starter kits and show major out‑of‑pocket savings — studies show heavy smokers switching to vaping can save up to ~£4,000–£5,000 a year. For someone focused on reducing spending, a well‑run vape clinic with behavioural support is attractive.

3. Smokers wanting a pragmatic, supported quit attempt

The best outcomes are likely where vape provision is integrated with behavioural support — whether that is delivered through GP‑linked stop‑smoking teams or community clinics. Commissioners should ensure both pathways are available and linked locally.

Product options to support a switch (examples)

When vapes are used as cessation aids, nicotine formulation and ease of use matter. For instance, nicotine salts and measured nicotine drops are common tools used to titrate nicotine safely during a quit attempt. Examples of products commonly supplied with starter kits include nicotine drops and longfill salt‑nicotine mixes that allow tailored strength and flavour choices. For instance, nicotine drops can help taper nicotine intake, while longfill salt blends support higher‑nicotine needs early in the quit attempt. Local services should stock regulated, quality‑assured products only; examples available through community suppliers include 0.5mg Tick Tock Nicotine Candy 12 Drops, and longfill salt options such as the Crystalize Bar Salts 120ml longfill (with nicotine shots) and the Crystalize Bar Salts 60ml longfill (with nicotine shots).

Conclusion

Ealing’s data underline two things: first, traditional referral routes can deliver validated quits but at a high local cost per quitter (£2,063) when referral volumes are low; second, nationally driven programmes such as Swap to Stop are changing the landscape by increasing vape use in quit attempts (Addiction, 2026) and by mobilising substantial funding to scale starter kits and support. NCSCT’s March 2026 guidance makes clear that integrating nicotine vapes into stop‑smoking services — with robust behavioural support — is best practice.

For commissioners the clear course is not an either/or choice but better integration: fund community vape clinics with standardised behavioural support and CO‑validation, and ensure GPs actively refer patients into these options. For smokers, the takeaway is pragmatic: seek services that combine quality‑assured nicotine products with behavioural support — that combination gives the best chance of quitting and of keeping your money in your pocket.